ArticleScientific reports2025
Evaluation of ovarian functions in girls treated for hematological malignancy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relationship between different modes of death and premature ovarian insufficiency: a literature review.Apoptosis : an international journal on programmed cell death · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lymphoblastic leukemia (ALL) and other hematological malignancies are the most common cancers in children, with chemotherapy and/or radiotherapy as the primary treatment options. These treatments, however, may have long-term effects on ovarian function and fertility in female survivors. This study aims to evaluate ovarian function and reserve in female survivors of childhood hematological malignancies by assessing hormonal markers and ovarian follicle count. This cross-sectional study included 30 female survivors of acute leukemia, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma (HL) who completed chemotherapy between 2013 and 2023. Hormonal markers including anti-Müllerian hormone (AMH), inhibin B, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), and ovarian follicle counts were measured. Statistical analysis was performed using SPSS, with a significance level of p < 0.05. Out of 263 patients diagnosed with hematological malignancies during the study period, 30 female patients were included. The median age at diagnosis was 14 years (range: 7-24 years). The malignancy breakdown was as follows: 7 patients (23.3%) with ALL, 2 patients (6.7%) with acute myeloid leukemia (AML), 9 patients (30%) with HL, and 12 patients (40%) with NHL. The median number of right ovarian follicles was 6 (range: 0-13), and the median number of left ovarian follicles was 7 (range: 2-12), with a total median follicle count of 12.5 (range: 5-25). AMH levels were normal in 26 patients (86.7%) and low in 3 patients (10%), with 3 patients (10%) diagnosed with decreased ovarian reserve (DOR), defined by AMH levels < 0.96 ng/mL. Inhibin-B levels were normal in 25 patients (83.3%), elevated in 1 patient (3.3%), and low in 4 patients (13.3%). Significant correlations were found between AMH and inhibin-B (p = 0.005, r = 0.508), FSH and inhibin-B (p = 0.041, r = 0.375), and inhibin-B and total follicle count (p = 0.014, r = 0.444). Additionally, a significant modarate correlation between AMH levels and total follicle count was observed (p = 0.033, r = 0.396). The evaluation of ovarian reserve using AMH, inhibin B, and ovarian follicle counts provides critical insights for fertility planning in survivors of childhood cancer. Early and comprehensive assessments may improve reproductive outcomes and quality of life for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.